Acute rejection in vascularized composite allotransplantation

Current Opinion in Organ Transplantation

Volumn 19, Issue 6, 2014, Pages 531-544

  Fischer, Sebastian ^a,b   Lian, Christine G ^a   Kueckelhaus, Maximilian ^a,c   Strom, Terry B ^d   Edelman, Elazer R ^a,e   Clark, Rachel A ^a   Murphy, George F ^a   Chandraker, Anil K ^a   Riella, Leonardo V ^a   Tullius, Stefan G ^a   Pomahac, Bohdan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Acute rejection; Face transplantation; Facial allograft; Hand transplantation; Vascularized composite tissue allotransplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BORTEZOMIB; COMPLEMENT INHIBITOR; CORTICOSTEROID; ECULIZUMAB; MOUTHWASH; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; CORTICOSTEROID THERAPY; ERYTHEMA; FACIAL TRANSPLANTATION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAND TRANSPLANTATION; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PATIENT CARE; PUVA; REVIEW; SKIN SWELLING; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION; ACUTE DISEASE; ANIMAL; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; SKIN; SKIN TRANSPLANTATION;

ACUTE DISEASE; ANIMALS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; SKIN; SKIN TRANSPLANTATION; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION;

EID: 84927691334     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000140     Document Type: Review

References (75)

1. Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet 1999; 353:1315-1320.
2. Petruzzo P, Dubernard JM. The International Registry on Hand and Composite Tissue allotransplantation. Clin Transpl 2011; 247-253.
3. Fischer S, Kueckelhaus M, Pautzenberger P, et al. Functional outcomes of face transplantation. Am J Transpl 2014. doi: 10.1111/ajt.12956.
4. Cendales L, Hardy MA. Immunologic considerations in composite tissue transplantation: overview. Microsurgery 2000; 20:412-419.
5. Chandraker A, Arscott R, Murphy GF, et al. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotrans-plant. Am J Transpl 2014; 14:1446-1452.
6. Bonastre J, Landin L, Diez J, et al. Factors influencing acute rejection of human hand allografts: a systematic review. Ann Plast Surg 2012; 68:624-629.
7. Guo S, Han Y, Zhang X, et al. Human facial allotransplantation: a 2-year follow-up study. Lancet 2008; 372:631-638.
8. Dorafshar AH, Bojovic B, Christy MR, et al. Total face, double jaw, and tongue transplantation: an evolutionary concept. Plast Reconstr Surg 2013; 131:241-251.
9. Kaufman CL, Ouseph R, Blair B, et al. Graft vasculopathy in clinical hand transplantation. Am J Transpl 2012; 12:1004-1016.
10. Kirk AD. Induction immunosuppression. Transplantation 2006; 82:593-602.
11. Thiyagarajan UM, Ponnuswamy A, Bagul A. Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol 2013; 37:586-601.
12. Khalifian S, Brazio PS, Mohan R, et al. Facial transplantation: the first 9 years. Lancet 2014; pii: S0140-6736(13)62632-X. doi: 10.1016/S0140-6736(13)62632-X. [Epub ahead of print]
13. Dubernard JM, Lengele B, Morelon E, et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med 2007; 357:2451-2460.
14. Devauchelle B, Badet L, Lengele B, et al. First human face allograft: early report. Lancet 2006; 368:203-209.
15. Lantieri L, Hivelin M, Audard V, et al. Feasibility, reproducibility, risks and benefits of face transplantation: a prospective study of outcomes. Am J Transplant 2011; 11:367-378.
16. Siemionow MZ, Papay F, Djohan R, et al. First U.S. near-total human face transplantation: a paradigm shift for massive complex injuries. Plast Reconstr Surg 2010; 125:111-122.
17. Gordon CR, Avery RK, Abouhassan W, Siemionow M. Cytomegalovirus and other infectious issues related to face transplantation: specific considerations, lessons learned, and future recommendations. Plast Reconstr Surg 2011; 127:1515-1523.
18. Ruegg EM, Hivelin M, Hemery F, et al. Face transplantation program in France: a cost analysis of five patients. Transplantation 2012; 93:1166-1172.
19. Cavadas PC, Ibanez J, Thione A. Surgical aspects of a lower face, mandible, and tongue allotransplantation. J Reconstr Microsurg 2012; 28:43-47.
20. Shanmugarajah K, Hettiaratchy S, Clarke A, Butler PE. Clinical outcomes of facial transplantation: a review. Int J Surg 2011; 9:600-607.
21. Sicilia-Castro D, Gomez-Cia T, Infante-Cossio P, et al. Reconstruction of a severe facial defect by allotransplantation in neurofibromatosis type 1: a case report. Transplant Proc 2011; 43:2831-2837.
22. Ben Marzouk-Hidalgo OJ, Cordero E, Gomez-Cia T, et al. First face composite-tissue transplant recipient successfully treated for cytomegalovirus infection with preemptive valganciclovir treatment. Antimicrob Agents Chemother 2011; 55:5949-5951.
23. Barret JP, Gavalda J, Bueno J, et al. Full face transplant: the first case report. Ann Surg 2011; 254:252-256.
24. Lierde KM, Roche N, Letter MD, et al. Speech characteristics one year after first Belgian facial transplantation. Laryngoscope 2014; 124:2021-2027.
25. Landin L, Cavadas PC, Ibanez J, et al. CD3+-mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab. Transplantation 2009; 87:776-781.
26. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355:1967-1977.
27. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; CD003897.
28. Penninga L, Wettergren A, Wilson CH, et al. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev 2014; 6:CD010253.
29. Terasaki PI. Selection of organ donors. N Engl J Med 1969; 280:1304.
30. Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 2014; 14:1573-1580.
31. Morath C, Opelz G, Zeier M, Susal C. Prevention of antibody-mediated kidney transplant rejection. Transpl Int 2012; 25:633-645.
32. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompa-tible kidney recipients and survival. N Engl J Med 2011; 365:318-326.
33. Jin MK, Cho JH, Kwon O, et al. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc 2012; 44:200-203.
34. Salvadori M, Bertoni E. Impact of donor-specific antibodies on the outcomes of kidney graft: pathophysiology, clinical, therapy. World J Transplant 2014; 4:1-17.
35. Riella LV, Safa K, Yagan J, et al. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Transplantation 2014; 97:1247-1252.
36. Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 2014; 98:312-319.
37. Ejaz NS, Shields AR, Alloway RR, et al. Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients. Am J Transplant 2013; 13:3142-3154.
38. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
39. Sharif A, Racusen L, Montgomery R, Kraus E. Risk for BK viremia and nephropathy after desensitization. Transplantation 2014; 98:e7-e8.
40. Brandacher G, Ninkovic M, Piza-Katzer H, et al. The Innsbruck hand transplant program: update at 8 years after the first transplant. Transplant Proc 2009; 41:491-494.
41. Petruzzo P, Testelin S, Kanitakis J, et al. First human face transplantation: 5 years outcomes. Transplantation 2012; 93:236-240.
42. Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012; 12:694-705.
43. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157-1167.
44. Gordon CR, Siemionow M, Papay F, et al. The world's experience with facial transplantation: what have we learned thus far? Ann Plast Surg 2009; 63:572-578.
45. Sarhane KA, Tuffaha SH, Broyles JM, et al. A critical analysis of rejection in vascularized composite allotransplantation: clinical, cellular and molecular aspects, current challenges, and novel concepts. Front Immunol 2013; 4:406.
46. Kanitakis J. The challenge of dermatopathological diagnosis of composite tissue allograft rejection: a review. J Cutan Pathol 2008; 35:738-744.
47. Pomahac B, Pribaz J, Eriksson E, et al. Restoration of facial form and function after severe disfigurement from burn injury by a composite facial allograft. Am J Transplant 2011; 11:386-393.
48. Kueckelhaus M, Fischer S, Lian C, et al. Utility of sentinel flaps in assessing facial allograft rejection. Plast Reconstr Surg 2014. [Epub ahead of print]
49. Starzl R, Brandacher G, Lee WP, et al. Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation. Clin Dev Immunol 2013; 2013:402980.
50. Kanitakis J, Badet L, Petruzzo P, et al. Clinicopathologic monitoring of the skin and oral mucosa of the first human face allograft: report on the first eight months. Transplantation 2006; 82:1610-1615.
51. Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991; 87:401-411.
52. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013; 381:313-319.
53. Siemionow M, Ozturk C. Face transplantation: outcomes, concerns, controversies, and future directions. J Craniofac Surg 2012; 23:254-259.
54. Lian CG, Bueno EM, Granter SR, et al. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Mod Pathol 2014; 27:788-799.
55. Cendales LC, Kanitakis J, Schneeberger S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant 2008; 8:1396-1400.
56. Saavedra AP, Bueno EM, Granter SR, Pomahac B. Transmission of donor-specific skin condition from donor to recipient of facial allograft. Am J Transplant 2011; 11:1340.
57. Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ Tcells are resident in normal skin. J Immunol 2006; 176:4431-4439.
58. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 2013; 31:137-161.
59. Gebhardt T, Mackay LK. Local immunity by tissue-resident CD8(+) memory T cells. Front Immunol 2012; 3:340.
60. Clark RA. Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol 2010; 130:362-370.
61. Hirahara K, Liu L, Clark RA, et al. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006; 177:4488-4494.
62. Petruzzo P, Kanitakis J, Badet L, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant 2011; 11:808-816.
63. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6:1578-1585.
64. ReitamoS, Remitz A. An updateon current pharmacotherapy optionsin atopic dermatitis. Expert Opin Pharmacother 2014; 15:1517-1524.
65. Schmook T, Kraft J, Benninghoff B, et al. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant 2005; 36:87-88.
66. Schneeberger S, Kreczy A, Brandacher G, et al. Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. Am J Transplant 2004; 4:1372-1374.
67. Wu L, Tam N, Deng R, et al. Steroid-resistant acute rejection after cadaveric liver transplantation: Experience from one single center. Clin Res Hepatol Gastroenterol 2014; pii: S2210-7401(14)00098-9. doi: 10.1016/j.clinre. 2014.04.005. [Epub ahead of print]
68. Marcussen N, Olsen TS, Benediktsson H, et al. Reproducibility of the Banff classification of renal allograft pathology. Inter- and intraobserver variation. Transplantation 1995; 60:1083-1089.
69. Wolfram D, Starzl R, Hackl H, et al. Insights from computational modeling in inflammation and acute rejection in limb transplantation. PLoS One 2014; 9:e99926.
70. Leto Barone AA, Sun Z, Montgomery RA, et al. Impact of donor-specific antibodies in reconstructive transplantation. Expert Rev Clin Immunol 2013; 9:835-844.
71. Leonard DA, Kurtz JM, Cetrulo CL Jr. Vascularized composite allotransplantation: towards tolerance and the importance of skin-specific immunobiology. Curr Opin Organ Transplant 2013; 18:645-651.
72. Starzl TE, Demetris AJ, Trucco M, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992; 340:876-877.
73. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
74. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4:124ra28.
75. Schneeberger S, Gorantla VS, Brandacher G, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg 2013; 257:345-351.